CoChat

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition

Open access
Roca-Portoles, Alba, Rodriguez-Blanco, Giovanny, Sumpton, David, Cloix, Catherine, Mullin, Margaret, Mackay, Gillian M., O’Neill, Katelyn, Lemgruber, Leandro, Luo, Xu, Tait, Stephen W. G. · 2020 · Cell Death & Disease
Cited by 100

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

BH3-mimetics are a new class of anti-cancer drugs that inhibit anti-apoptotic Bcl-2 proteins. In doing so, BH3-mimetics sensitise to cell death. Venetoclax is a potent, BCL-2 selective BH3-mimetic that is clinically approved for use in chronic lymphocytic leukaemia. Venetoclax has also been shown to inhibit mitochondrial metabolism, this is consistent with a proposed role for BCL-2 in metabolic regulation. We used venetoclax to understand BCL-2 metabolic function. Similar to others, we found that venetoclax inhibited mitochondrial respiration. In addition, we also found that venetoclax impairs TCA cycle activity leading to activation of reductive carboxylation. Importantly, the metabolic effects of venetoclax were independent of cell death because they were also observed in apoptosis-resistant BAX/BAK-deficient cells. However, unlike venetoclax treatment, inhibiting BCL-2 expression had no effect on mitochondrial respiration. Unexpectedly, we found that venetoclax also inhibited mitochondrial respiration and the TCA cycle in BCL-2 deficient cells and in cells lacking all anti-apoptotic BCL-2 family members. Investigating the basis of this off-target effect, we found that venetoclax-induced metabolic reprogramming was dependent upon the integrated stress response and ATF4 transcription factor. These data demonstrate that venetoclax affects cellular metabolism independent of BCL-2 inhibition. This off-target metabolic effect has potential to modulate venetoclax cytotoxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-020-02867-2

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 100

Metadata

Authors
Roca-Portoles, A., Rodriguez-Blanco, G., Sumpton, D., Cloix, C., Mullin, M., Mackay, G. M., O’Neill, K., Lemgruber, L., Luo, X., & Tait, S. W. G.
Venue
Cell Death & Disease
Published
2020-08-13
Volume
11
Issue
8
Pages
616-616
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3048513522
Cited by
100
References
14
FWCI
3.39
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. https://app.cochat.ai/papers/10.1038/s41419-020-02867-2
The paper
Roca-Portoles, A., Rodriguez-Blanco, G., Sumpton, D., Cloix, C., Mullin, M., Mackay, G. M., O’Neill, K., Lemgruber, L., Luo, X., & Tait, S. W. G. (2020). Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death & Disease. https://doi.org/10.1038/s41419-020-02867-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.